MARKET

NKTX

NKTX

Nkarta, Inc.
NASDAQ
3.030
0.000
0.00%
After Hours: 3.021 -0.009 -0.30% 18:25 05/22 EDT
OPEN
3.100
PREV CLOSE
3.030
HIGH
3.220
LOW
3.005
VOLUME
357.11K
TURNOVER
--
52 WEEK HIGH
3.650
52 WEEK LOW
1.630
MARKET CAP
216.78M
P/E (TTM)
-2.2463
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at NKTX last week (0511-0515)?
Weekly Report · 5d ago
Nkarta Insider Stock Sellers Must Be Relieved As Market Cap Falls To US$201m
Simply Wall St · 05/15 11:13
Nkarta (NKTX) Gets a Buy from Stifel Nicolaus
TipRanks · 05/13 15:15
Nkarta Price Target Maintained With a $11.00/Share by Needham
Dow Jones · 05/13 10:55
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), PROCEPT BioRobotics (PRCT) and Lineage Therap (LCTX)
TipRanks · 05/13 10:50
Needham Reiterates Buy on Nkarta, Maintains $11 Price Target
Benzinga · 05/13 10:45
Nkarta Buy Rating Reaffirmed as NKX019 Autoimmune Trials Advance; $16 Price Target Maintained
TipRanks · 05/13 10:19
Nkarta reports Q1 EPS (37c), consensus (37c)
TipRanks · 05/12 22:15
More
About NKTX
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.

Webull offers Nkarta Inc stock information, including NASDAQ: NKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NKTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NKTX stock methods without spending real money on the virtual paper trading platform.